Olema Pharmaceuticals Company Insiders
OLMA Stock | USD 4.23 0.11 2.67% |
Olema Pharmaceuticals employs about 16 people. The company is managed by 16 executives with a total tenure of roughly 38 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Olema Pharmaceuticals' management performance can provide insight into the company performance.
Olema |
Olema Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2443) % which means that it has lost $0.2443 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3906) %, meaning that it created substantial loss on money invested by shareholders. Olema Pharmaceuticals' management efficiency ratios could be used to measure how well Olema Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Olema Pharmaceuticals Workforce Comparison
Olema Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,734. Olema Pharmaceuticals maintains roughly 16.0 in number of employees contributing less than 1% to equities under Health Care industry.
Olema Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Olema Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Olema Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Olema Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bohen Sean over three weeks ago Acquisition by Bohen Sean of 650000 shares of Olema Pharmaceuticals at 4.37 subject to Rule 16b-3 | ||
Mitchell Shawnte over a month ago Insider Trading | ||
Bain Capital Life Sciences Investors, Llc over two months ago Insider Trading | ||
Graham G. Walmsley over three months ago Disposition of 700761 shares by Graham G. Walmsley of Olema Pharmaceuticals at 6.75 subject to Rule 16b-3 | ||
Zojwalla Naseem over three months ago Disposition of 14000 shares by Zojwalla Naseem of Olema Pharmaceuticals at 4.87 subject to Rule 16b-3 | ||
Graham G. Walmsley over three months ago Disposition of 700761 shares by Graham G. Walmsley of Olema Pharmaceuticals at 6.75 subject to Rule 16b-3 | ||
Bohen Sean over three months ago Disposition of 1267 shares by Bohen Sean of Olema Pharmaceuticals at 9. subject to Rule 16b-3 | ||
Bvf Partners L P/il over three months ago Acquisition by Bvf Partners L Pil of 153441 shares of Olema Pharmaceuticals at 1.0E-4 subject to Rule 16b-3 |
Olema Pharmaceuticals Notable Stakeholders
An Olema Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Olema Pharmaceuticals often face trade-offs trying to please all of them. Olema Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Olema Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sasha CPA | VP Controller | Profile | |
JD Moriarty | Corporate Secretary | Profile | |
Peter Kushner | CoFounder Fellow | Profile | |
PharmD Faltaos | VP Pharmacology | Profile | |
Kinney Horn | Chief Officer | Profile | |
Cyrus Harmon | Chief Director | Profile | |
Courtney Dugan | VP Communications | Profile | |
John Moriarty | Chief VP | Profile | |
Moriarty ESQ | Corporate Secretary | Profile | |
Shane MBA | Chief Officer | Profile | |
Julie Dexter | Senior People | Profile | |
Courtney OKonek | Vice Communications | Profile | |
Naseem MD | Chief Officer | Profile | |
David Myles | Chief Officer | Profile | |
Geoffrey Mogilner | Vice Communications | Profile | |
Shawnte JD | Chief Secretary | Profile |
About Olema Pharmaceuticals Management Performance
The success or failure of an entity such as Olema Pharmaceuticals often depends on how effective the management is. Olema Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Olema management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Olema management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for womens cancers. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Olema Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Please note, the presentation of Olema Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Olema Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Olema Pharmaceuticals' management manipulating its earnings.
Olema Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Olema Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Olema Pharmaceuticals within its industry.Olema Pharmaceuticals Manpower Efficiency
Return on Olema Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 8.1M | |
Net Loss Per Executive | 8.1M | |
Working Capital Per Employee | 24.8M | |
Working Capital Per Executive | 24.8M |
Complementary Tools for Olema Stock analysis
When running Olema Pharmaceuticals' price analysis, check to measure Olema Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Olema Pharmaceuticals is operating at the current time. Most of Olema Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Olema Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Olema Pharmaceuticals' price. Additionally, you may evaluate how the addition of Olema Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |